CD8A and neoplasm: This exploration led to the identification of a combination of TLR agonists that can effectively facilitate the ex vivo expansion of PD-1+ subpopulation of CD8+ T cells from blood of cancer patients, which represent a potential repertoire of tumor-reactive CD8+ T cells.